The role of TAFs in transcriptional regulation has been intensely studied in vitro as well as in vivo over the past several years (reviewed in references 3, 5, 32, and 40). Results from the early in vitro studies have revealed that TAFs play an essential role in mediating transcriptional activation by a variety of activators, and as such, they are considered coactivators. TAFs have been shown to directly contact selected activators, and these interactions are required for activated transcription in vitro. In vivo studies conducted with yeast, however, have suggested that TAFs may not be required at all gene promoters to regulate transcription (29, 47) . Further work has revealed that they may be essential for transcription of selected genes that govern the cell cycle progression in yeast (1, 48). Studies carried out with the Drosophila embryo have also demonstrated that specific TAF-activator interactions are required for activation of selected genes in vivo (41).
The role of TAFs in transcriptional regulation has been intensely studied in vitro as well as in vivo over the past several years (reviewed in references 3, 5, 32, and 40) . Results from the early in vitro studies have revealed that TAFs play an essential role in mediating transcriptional activation by a variety of activators, and as such, they are considered coactivators. TAFs have been shown to directly contact selected activators, and these interactions are required for activated transcription in vitro. In vivo studies conducted with yeast, however, have suggested that TAFs may not be required at all gene promoters to regulate transcription (29, 47) . Further work has revealed that they may be essential for transcription of selected genes that govern the cell cycle progression in yeast (1, 48) . Studies carried out with the Drosophila embryo have also demonstrated that specific TAF-activator interactions are required for activation of selected genes in vivo (41) .
hTAF II 130 is a human homolog of Drosophila TAF II 110 (dTAF II 110), the first TAF demonstrated to possess coactivator activity (6, 20) . Unlike other TAFs, hTAF II 130 and dTAF II 110 display limited sequence similarities (26, 45) . hTAF II 130 is also unique among TAFs in that no apparent homolog exists in yeast. Furthermore, hTAF II 130 may be the product of a member of a gene family, since at least one additional related but distinct gene product, hTAF II 105, has been found in the TFIID complex purified from differentiated B cells (11) .
Protein-protein interaction assays as well as in vitro transcription assays have provided evidence for direct interaction of activators with one or more TAFs in the TFIID complex (6, 17, 20, 21) . Significantly, such studies have suggested that different activators may interact selectively with specific TAF proteins. For example, glutamine-rich activation domains of Sp1 and the cyclic AMP-responsive transcription factor CREB bind hTAF II 130 (45) and dTAF II 110 (14, 20) , the activation domains of VP16 and p53 bind hTAF II 32 (23, 24) and dTAF II 40 (17, 23, 24, 46) , the retinoblastoma susceptibility gene product binds hTAF II 250 (42) , and the estrogen receptor interacts with hTAF II 30 that is present in a subset of TFIID complex (21) . These interactions are thought to participate in the recruitment and/or stabilization of the preinitiation complex at the promoter, leading to increased levels of transcription. TAFs may also play a role in positioning TFIID onto promoter DNA, in conjunction with TFIIA. In the context of promoter-bound TFIID, site-specific photo-cross-linking of hTAF II 130 to the adenovirus major late promoter was observed (31) . Furthermore, Drosophila TAF II 60 was shown to bind to the conserved downstream core promoter element (2) , while a recent study indicated that yeast TAF II 145 functions to recognize selected core promoters (43) . It is evident from these studies that TAFs serve multiple functions as a coactivator and a promoter selectivity factor. In addition, a regulatory function has been suggested for TAFs, as recent findings indicate that TAF II 250 contains protein kinase (10) and histone acetyltransferase (28) activities. As integral components of the preinitiation complex, TAFs also participate in protein-protein interactions with components of the general transcription machinery (3) .
As a step towards understanding the function of hTAF II 130, we have identified the regions of several activators that interact with hTAF II 130. We then compared and contrasted these activator-TAF interactions by using individual activators and deletions of hTAF II 130. This analysis of TAF-activator interactions should provide an understanding of how multiple activators cooperate to activate transcription by targeting the same TAF protein in the general transcription machinery.
The human transcription factor Sp1 contains glutamine-rich activation domains, A and B (9 
MATERIALS AND METHODS
Construction of C-terminal and N-terminal deletion derivatives of hTAF II 130. All hTAF II 130 derivatives used in this study were cloned into the pEG202 vector downstream of the LexA DNA binding domain (DBD) (18) and in frame with the introduced hemagglutinin antigen (HA) tag. For construction of C-terminal deletion derivatives, pAS-hTAF II 130 (residues 270 to 947) was linearized at the 3Ј end of the hTAF II 130 cDNA sequence and digested with nuclease Bal 31 at 30°C for different times as described previously (37). Each deletion pool was then digested with EcoRI (upstream of the HA tag in pAS [12] ), and the DNA fragments were purified and ligated to pEG202 digested with EcoRI and BamHI (blunt ended). For construction of N-terminal deletion derivatives, pAShTAF II 130N/C (residues 270 to 700) (45) was linearized with EcoRI at the 5Ј end of the insert sequence and digested with nuclease Bal 31 at 25°C, followed by digestion with SalI. The DNA fragments were gel purified and subcloned into NcoI (blunt ended) and SalI sites in pEG202 downstream of the LexA DBD and the introduced HA tag sequence. All constructs were sequenced across the cloning junction to select for the deletions that were in frame with the LexA DBD.
Yeast two-hybrid methods. The pEG202-hTAF II 130 deletion derivatives and the pJG4-5 vector (18) constructs encoding the B42 transcriptional activation domain fused to Sp1A (residues 83 to 262), Sp1B (residues 263 to 542) (a gift of Grace Gill, Harvard Medical School), or CREB-N (residues 3 to 296) were cotransformed into yeast strain EGY48 as described previously (20) . Mutants of the Sp1B and Sp1B-c (residues 421 to 542) activation domains, cloned into the pGAD vector (16) (gifts of G. Gill), were cotransformed into yeast strain W303 with pEG202-hTAF II 130N/C (residues 270 to 700) as described previously (45) . The transformed yeast cells were grown on a selection medium containing X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) for qualitative detection of the ␤-galactosidase activity. For quantitative ␤-galactosidase assays, transformed yeast cells were grown in a liquid selection medium for 24 to 36 h before induction (overnight), and ␤-galactosidase activity was measured in triplicate as described previously (15) . Each experiment was repeated a minimum of three times. The expression of the fusion proteins was confirmed by immunoblotting with anti-HA antibody.
Transient-transfection assays with cultured mammalian cells. The pSG424 vector (36) constructs carrying the Gal4 DBD (residues 1 to 147) fused to Sp1A/B (residues 83 to 621), Sp1B (residues 263 to 542), Sp1B-c (residues 421 to 542), and their mutant derivatives were generous gifts of G. Gill (16) . COS cells were transfected with a Gal4-Sp1 fusion construct and a UASp59RLG reporter plasmid (a gift of David Ron, New York University Medical Center) containing two copies of the Gal4 binding site upstream of the minimal angiotensinogen promoter (35) , using the DEAE-dextran method as described previously (37) . Transient transfections in HeLa cells were performed by using Lipofectamine (Life Technologies, Inc.) according to the manufacturer's instructions with minor modifications. Quantities of the cytomegalovirus (CMV)-driven expression plasmid DNA containing subdomains of HA-⌬NhTAF II 130 (amino acids 1 to 947) (45) were optimized for comparable levels of protein expression (see Fig. 5 ) as determined by immunoblotting with anti-HA antibody and an ECL chemiluminescence detection kit (Amersham Life Science). Each transfection in HeLa cells included a fixed amount of CMVhTAF II 130 derivative and/or empty CMV vector as well as CMVlacZ (0.15 g), 5xGal4-E1b-luciferase reporter (44) (0.5 to 0.75 g), and one of the following activators in the pSG424 vector: Gal4-Sp1A/B (0.25 g), Gal4-Sp1B (0.25 g), or Gal4-VP16 (0.05 g). The HA-tagged CMVhTAF II 130 derivatives utilized were as follows: wild-type hTAF II 130 (residues 1 to 947) (2 g), hTAF II 130N/C (residues 270 to 700) (1.25 to 3 g), derivative 4 (residues 270 to 700/⌬454-525) (3 g), derivative 10 (residues 270 to 409) (0.25 g), derivative 13 (residues 270 to 350) (2 g), N334 (residues 1 to 334) (0.1 g), N288 (residues 1 to 288) (0.09 g), and N297 (residues 1 to 297) (0.075 g). At 40 h posttransfection, cells were washed twice in phosphate-buffered saline and harvested in 1ϫ Reporter Lysis Buffer (Promega). Luciferase activity was quantified in a reaction mixture containing 25 mM glycylglycine (pH 7.8), 15 mM MgSO 4 , 1 mM ATP, 0.1 mg of bovine serum albumin per ml, and 1 mM dithiothreitol. A Lumat LB 9507 luminometer (EG&G Berthold) was used to measure activity with 1 mM D-luciferin (Analytical Luminescence Laboratory) as the substrate. All transfections were performed in duplicate a minimum of three times.
RESULTS
The first glutamine-rich domain (Q1) within the central region of hTAF II 130 is sufficient for interaction with activation domain B of Sp1. Using the yeast two-hybrid system, we previously found that the central region (residues 270 to 700) of hTAF II 130 (designated hTAF II 130N/C) was sufficient to interact with activation domain B of Sp1 (Sp1B) (45) . To further define subregions of the hTAF II 130 central domain for interaction with Sp1B, we generated a series of N-terminal and C-terminal deletions of hTAF II 130. Deletion mutants of hTAF II 130 were subcloned into a yeast plasmid downstream of the LexA DBD/HA tag sequence and tested for their ability to interact with the Sp1B domain.
The central region of hTAF II 130 contains four glutaminerich regions (designated Q1 to Q4) (see the legend to Fig. 1 ). Figure 1 shows the results of the interaction assay with Sp1B and the C-terminal deletion mutants of hTAF II 130. Surprisingly, the hTAF II 130 C-terminal deletion mutants lacking the Q2, Q3, and Q4 glutamine-rich regions had little effect on the interaction with Sp1B (derivatives 1 to 12). hTAF II 130 containing only the Q1 region (derivative 13) was found to be sufficient for interaction with Sp1B. Deletion of Q1 (derivative 15) reduced the interaction to 28%. The central region of hTAF II 130 contains a sequence (CI, residues 449 to 528) that has a high degree of similarity with dTAF II 110 (45) . We tested a derivative lacking most of the CI sequence (derivative 4) and found that the conserved sequence CI was not required for interaction of hTAF II 130 with Sp1B. Although derivatives 6 to 8 were found to be weakly active in the absence of Sp1B, they still showed significant interactions with Sp1B, as the ␤-galactosidase activity measured was significantly enhanced over the basal levels in the presence of Sp1B (data not shown). The expression of all mutant hTAF II 130 proteins was confirmed by immunoblotting of the yeast cell lysates with anti-HA antibody (data not shown).
To test whether other glutamine-rich regions of hTAF II 130 (Q2, Q3, and Q4) could functionally substitute for Q1, we tested a series of N-terminal deletion mutants of hTAF II 130 in the yeast two-hybrid system. As shown in Fig. 2 , deletion of a region containing Q1 (derivative 18) severely decreased (to 4.4%) the ability of hTAF II 130 to interact with Sp1B even in the presence of other glutamine-rich regions. These results suggest that a domain within amino acids 270 to 350 of hTAF II 130 (derivative 13) contains the sequences important for interaction with Sp1B and that the other domains (Q2, Q3, and Q4) cannot functionally substitute for Q1.
Different activators interact with distinct regions of hTAF II 130. The central portion of hTAF II 130, like dTAF II 110, also interacts with activation domain A of Sp1 (Sp1A) and the N-terminal activation domain of CREB (CREB-N) (14, 20, 45) . We wanted to test whether these activators interacted with a common region or distinct regions within hTAF II 130. The hTAF II 130 deletion mutants described above were tested for their interaction with Sp1A and CREB-N by using the yeast two-hybrid system. As shown in Fig. 3 , deletion of a region containing Q1 (derivative 18) of hTAF II 130 did not impair its interaction with Sp1A. This is in contrast to the result obtained with Sp1B (compare results with derivative 18 in Fig. 2 and 3) , where deletion of Q1 virtually eliminated interaction. hTAF II 130 lacking Q1 and a portion of Q2 (derivative 19) retained 43% of the activity with Sp1A, whereas the same construct interacted poorly with Sp1B (2.1%) (derivative 19 in Fig. 2) . Interestingly, derivative 10 ( Fig. 3) , containing Q1 and Q2, interacted with Sp1A (42%) as well as derivative 21 (Fig.  3) , which contained Q3 and Q4 (42%). This finding suggests that unlike Sp1B, Sp1A makes multiple contacts with hTAF II 130. We also observed that Sp1A interacted more strongly with hTAF II 130 than did Sp1B (30 to 60% higher activity) (data not shown). Sp1A was also shown to interact FIG. 1. Carboxyl-terminal deletion analysis of hTAF II 130 reveals the Q1 region to be important for interaction with Sp1B. Derivatives of hTAF II 130 fused to the LexA DBD in pEG202 are shown schematically. Yeast (EGY48) was transformed with pEG202-hTAF II 130 fusion constructs and an Sp1B (residues 263 to 542) fusion construct in pJG4-5 along with the reporter plasmid. The percent ␤-galactosidase activity relative to that of hTAF II 130N/C in each transformant is represented at the right. Asterisks indicate hTAF II 130 derivatives that activate weakly in the absence of Sp1B. All assays were done in triplicate. Expression of hTAF II 130 deletion mutants and Sp1B was confirmed by immunoblotting (data not shown). Q1, residues 300 to 347, 25% glutamine content; Q2, residues 388 to 419, 25% glutamine content; Q3, residues 528 to 550, 30% glutamine content; Q4, residues 580 to 651, 19% glutamine content. The numbering of the amino acid residues is as in reference 45. with the N-terminal 308 amino acids of dTAF II 110, which exclude most of the highly conserved domain CI (20) . Thus, dTAF II 110 and hTAF II 130 may have additional structural similarities, not apparent in the primary amino acid sequence, that permit their interactions with Sp1A.
The N-terminal glutamine-rich activation domain of CREB, on the other hand, preferentially interacted with a region encompassing Q1 and Q2 of hTAF II 130. Unlike the case for Sp1B, deletion of Q1 did not impair the interaction of hTAF II 130 with CREB-N (compare results with derivative 18 in Fig. 2 and 3) ; however, deletion of the sequences between Q1 and Q2 (derivative 19; Fig. 3 ) reduced the activity with CREB-N to 14%. Furthermore, derivatives 11 to 13, which contained Q1 and a partial Q2, interacted with CREB-N at reduced levels, suggesting additional interactions between Q2 and CREB-N. Interestingly, the C-terminal half of hTAF II 130, containing Q3 and Q4, did not interact efficiently with CREB-N, unlike with Sp1A (derivatives 20 and 21 in Fig. 3 ). Based on the hTAF II 130 N-terminal (derivatives 18 and 19) and C-terminal (derivatives 10 and 12) deletion constructs, a region involved in interaction with CREB-N appeared to encompass Q1 and Q2. This is in contrast to the interactions of Sp1A with hTAF II 130 (Q1 to Q4) and of Sp1B with hTAF II 130 (Q1). Thus, different activation domains appear to interact with distinct subdomains of hTAF II 130.
The ability of mutants of Sp1B to interact with hTAF II 130 correlates with their ability to activate transcription in mammalian cells. To demonstrate that Sp1B-hTAF II 130 interaction correlates with Sp1's ability to activate transcription, we tested previously characterized mutants of Sp1B (16) in the yeast two-hybrid system with hTAF II 130 (Fig. 4) . Linker substitution mutations in the carboxyl-terminal half of the Sp1B domain (M37 and M38) resulted in a 65 to 91% decrease in the ability of Sp1B to interact with hTAF II 130 (Fig. 4A) . Although the C-terminal subdomain of Sp1B (Sp1B-c) was sufficient to interact with hTAF II 130, substitution mutants Bc/M37 and B-c(W3A) interacted poorly with hTAF II 130 (Fig. 4B) , supporting the above-described finding that the C-terminal half of Sp1B contains the sequences required for interaction with hTAF II 130. As with dTAF II 110 (16), the replacement of two glutamines and one asparagine with alanine residues did not affect the interaction of the mutant B-c (Q3A) with hTAF II 130. 
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To correlate the ability of the Sp1B derivatives to interact with hTAF II 130 with their ability to activate transcription in mammalian cells, we tested the expression of a luciferase reporter gene containing the Gal4 binding sites by cotransfection of plasmids expressing Gal4-Sp1B-c or its mutant derivatives into COS cells. Gal4-Sp1B-c efficiently activated the reporter gene (90 to 100% of the activation by Gal4-Sp1B [data not shown]), whereas Gal4-DBD showed 5 to 10% of the activity of Gal4-Sp1B-c (data not shown). The linker substitution mutation significantly compromised the activation of the reporter gene (Sp1B-c/M37) (24%), as did the W3A substitution mutation in Sp1B-c (6%) (Fig. 4B) . By contrast, Sp1B-c bearing the Q3A mutation retained activity close to that of the wild type. Thus, Sp1B-c mutants that interacted poorly with hTAF II 130 in the yeast two-hybrid assay also failed to direct efficient transcription of the reporter gene in mammalian cells. Fig. 5A . The amount of DNA transfected was adjusted so as to achieve comparable levels of protein expression, as shown in the representative anti-HA immunoblot (Fig. 5B) . Cotransfection of a reporter construct bearing five Gal4 binding sites with a plasmid expressing the Gal4-Sp1A/B activator directed a high level of luciferase activity, which was decreased three-to fourfold in the presence of two hTAF II 130 subdomains, hTAF II 130N/C and derivative 4 (Fig. 5C ). By contrast, constructs N334 and FIG. 3 . Different activators interact with distinct regions within hTAF II 130. pEG202-hTAF II 130 derivatives were cotransformed into yeast with pJG4-5 plasmids expressing either Sp1A (residues 83 to 262) or CREB-N (residues 3 to 296) along with the reporter plasmid. All other conditions were as described in the legend to Fig. 1 . The hTAF II 130 derivatives shown have the same numbers as in Fig. 1 and 2 . The ␤-galactosidase activity of hTAF II 130N/C measured with pJG4-5-activator fusions was taken as 100%. ND, not determined. N288, expressing the N-terminal subdomains of hTAF II 130, had no detectable effect on Gal4-Sp1A/B-mediated transcription. The finding that a deletion of the conserved region CI (derivative 4) did not affect the ability of the hTAF II 130 central domain to inhibit transcription is in agreement with the result from the yeast two-hybrid system in which the ⌬CI construct remained capable of interacting with Sp1 (derivative 4 in Fig.  1 ). Additionally, construct N334, expressing a portion of Q1, did not inhibit activation by Sp1A/B, suggesting that additional Q regions are necessary for full inhibition of Sp1A/B.
We next tested the effects of transiently expressing the wildtype hTAF II 130 cDNA (amino acids 1 to 947) as well as derivatives carrying a subset of Q-rich regions (Fig. 6A) on the reporter gene activated by Gal4-Sp1B. Derivatives 10 and 13 contain the same hTAF II 130 sequences as those shown to interact with Sp1B in the yeast two-hybrid system (derivatives 10 and 13 in Fig. 1 ). We found that wild-type hTAF II 130 (amino acids 1 to 947), as well as derivatives 10 and 13, decreased Gal4-Sp1B-mediated reporter gene activity but that the N-terminal subdomain N297 did not (Fig. 6B) . To demonstrate that the squelching effect was specific for Sp1B, the Gal4-driven reporter gene was cotransfected with a plasmid expressing Gal4-VP16. Figure 6C shows that coexpression of hTAF II 130 subdomains had little effect on the Gal4-VP16-mediated activation of transcription, suggesting that the hTAF II 130 central domain had a specific effect on Sp1-mediated transcrip- (16) were tested for interaction with hTAF II 130 in the yeast two-hybrid assay. Yeast (W303) was cotransformed with pEG202-hTAF II 130N/C and Sp1B mutants in pGAD. The percent ␤-galactosidase activity was measured relative to that of the wild-type Sp1B. (B) Substitution mutants of Sp1B-c were tested for interaction with hTAF II 130 in the yeast two-hybrid assay. Sp1B-c mutants in pGAD were transformed into yeast along with pEG202-hTAF II 130N/C. The percent ␤-galactosidase activity was measured relative to that of the wild-type Sp1B-c. To determine the transcriptional activities of these Sp1B-c mutants, plasmids expressing the indicated Sp1B mutants fused to the Gal4 DBD were transfected into COS cells along with a Gal4-driven luciferase reporter gene and assayed for activation of transcription. The resulting luciferase activity was expressed relative to the activity of the wild-type Sp1B-c domain. All assays were done in triplicate.
VOL. 18, 1998 hTAF II 130 SUBDOMAINS REQUIRED FOR ACTIVATOR INTERACTION 5739 tion. In these experiments, hTAF II 130N/C, derivative 10, and N297 were expressed at comparable levels, whereas hTAF II 130 (amino acids 1 to 947) and derivative 13 were expressed at lower levels (data not shown). Similar results were obtained with different concentrations of activator proteins; thus, domain-specific transcriptional inhibition by hTAF II 130 was observed over a broad range of the reporter gene activity (data not shown). Taken together, the TAF-activator interaction studies carried out with yeast and cultured mammalian cells indicate that different activators bind distinct subdomains of hTAF II 130 and suggest a mechanism for coordinated action of multiple promoter-bound activators on the general transcription machinery.
DISCUSSION
Interactions between multiple activation domains and hTAF II 130. Recent studies on transcriptional activators that bind to enhancers to form a stereospecific enhanceosome complex have revealed multiple protein-protein contacts between DNA-bound activators, as well as between activators and their target proteins. It has been proposed that such extended networks of protein-protein interactions contribute to transcriptional synergy (reviewed in reference 4). For example, transcriptional activators bound to beta interferon enhancer appear to contact multiple regions of their target protein CBP (CREB-binding protein) or components of the basal transcriptional machinery to enhance transcription (22, 27) . A previous study has already established that interactions between activators with multiple members of the general transcription machinery lead to synergistic transcription (7). It has also been shown with the Drosophila hunchback promoter that specific activator-TAF interactions are sufficient for simple as well as synergistic activation by multiple enhancer factors (38, 39) . Thus, transcriptional synergy may be achieved by multiple proteinprotein interactions between single or multiple domains of activators and single or multiple surfaces of their target proteins.
The results presented in this paper suggest that distinct subdomains of hTAF II 130 might also serve as targets for multiple transcriptional activation domains. Using N-and C-terminal deletion mutants of the hTAF II 130 central domain, we demonstrate that specific regions within this domain are required for interaction with the glutamine-rich activation domains A and B of Sp1 and CREB. The central domain of Fig. 1). (B and C) Luciferase activity in the lysates of HeLa cells transfected with the reporter construct, the indicated hTAF II 130 derivative, and Gal4-Sp1B (B) or Gal4-VP16 (C) was determined. Although not shown in panel C, N297 was also tested with Gal4-VP16 in a separate experiment, and like other hTAF II 130 derivatives, it was found to have no significant effect on the transcriptional activation by Gal4-VP16. Although the majority of hTAF II 130 derivatives fused to the LexA DBD were transcriptionally inactive in yeast, C-terminal truncations that fell between residues 540 and 587 (Fig. 1) were found to be weakly active in the absence of Sp1. Interestingly, further removal of part of the highly conserved CI sequence from the truncated hTAF II 130 derivatives abolished self-activation (derivative 9 [ Fig. 1]) , suggesting that self-activation might have been caused by unmasking of the intact CI sequence. Although the function of CI is yet to be determined, the C-terminal conserved region CII in dTAF II 110 is required for interaction with dTAF II 250, dTAF II 30␣, and TFIIA-L (41, 45, 49) , suggesting that CI might also serve a conserved function. Perhaps unmasking of the hTAF II 130 CI sequence in yeast may have permitted interaction(s) with a conserved domain of a yeast TAF or a general transcription factor, leading to tethering of the transcription machinery to the promoter and activation of the reporter gene (34) .
Functional significance of the Sp1-hTAF II 130 interactions. We have also observed that Sp1A interacted more strongly with hTAF II 130 than did Sp1B in the yeast two-hybrid assay and in vitro binding assay (data not shown), similar to the observations made with dTAF II 110 (20) . Perhaps multiple contacts made between Sp1A and subdomains of hTAF II 130 may explain why Sp1A functions as a more potent activator than Sp1B in transient-transfection studies (9) . Since distinct regions of hTAF II 130 are targeted by Sp1A and B domains, these two domains in full-length Sp1 are likely to interact cooperatively with hTAF II 130 in vivo. Indeed, it has been shown that domains A and B, in addition to the carboxyl-terminal domain D, are all required for synergistic activation by Sp1 (33) . Interestingly, the carboxyl-terminal domain of Sp1 that includes the zinc finger DBD and domain D has been shown to interact with hTAF II 55 (8) . Thus, binding of Sp1 to different TAFs as well as different regions of the same TAF could result in cooperative interactions between Sp1 and TFIID and strong activation of transcription by the full-length Sp1 protein. It is worth noting that CREB also possesses two discrete activation domains, the kinase-inducible domain and the glutamine-rich activation domain Q2, both of which have been shown to be required for signal-dependent activation of transcription in vitro (30) . The phosphorylation-dependent kinase-inducible domain has been shown to interact with RNA polymerase II via the coactivator CBP, and the Q2 activation domain appears to recruit TFIID via hTAF II 130. These experiments suggest that multiple interactions between an activator and the components of the transcriptional machinery are required for full activity of CREB.
It has been demonstrated that the carboxyl-terminal half of the Sp1B domain (Sp1B-c) is sufficient for interaction of Sp1B with dTAF II 110 and that mutants of Sp1B-c that failed to interact with dTAF II 110 also activated transcription at reduced levels in Drosophila Schneider cells (16) . We have shown in the present study that the same mutants of Sp1B-c interacted poorly with hTAF II 130 and were compromised for their ability to activate transcription in mammalian cells. Thus, both in insect cells and in mammalian cells we find a correlation between the ability of Sp1 to interact with hTAF II 130 or dTAF II 110 and its ability to activate transcription. Moreover, despite the differences in the primary amino acid sequences between the hTAF II 130 central domain and the amino terminus of dTAF II 110, both proteins appear to interact with Sp1B in an analogous manner, suggesting a functional conservation between the two TAF proteins. It remains to be seen whether the interacting surfaces have similar structural characteristics.
Effects of transiently expressing hTAF II 130 in cultured cells. We have found that transient expression of the central domain of hTAF II 130 containing Q1 to Q4 (hTAF II 130N/C) as well as of subdomains of hTAF II 130 containing Q1 alone (derivative 13) or Q1 and Q2 (derivative 10) decreased transcriptional activation of the reporter gene by Gal4-Sp1B, consistent with the finding that Sp1B interacted strongly with Q1 in the yeast two-hybrid study. In the same transient-transfection assay, we also found that wild-type hTAF II 130 (amino acids 1 to 947) inhibited transcription by Gal4-Sp1B (Fig. 6B) . It was previously reported that transient expression of full-length dTAF II 110 did not affect transcriptional activation by Sp1 in insect cells (13) . It is possible that overexpression of dTAF II 110 was not sufficient to block activation by the full-length Sp1 used in that experiment, since full-length Sp1 has multiple potential targets within TFIID, including hTAF II 55, as discussed above. By contrast, in another study, transient expression of the full-length as well as the C-terminal portions of hTAF II 130 was reported to significantly enhance transcription of the reporter genes driven by the AF-2 activation domains of the retinoic acid, vitamin D 3 , and thyroid hormone receptors (26) . The authors of that study found hTAF II 130 to be limiting in vivo in some cell lines and thus speculated that overexpression might result in an increase in TFIID available for recruitment to promoters driven by AF-2. Interestingly, unlike the glutamine-rich activation domains described in this paper, AF-2 domains of selected nuclear receptors did not directly contact hTAF II 130. The authors proposed that hTAF II 130 might contact a common intermediary protein(s) that binds AF-2 domains in a subset of nuclear receptors. Finally, the conserved C-terminal 105 amino acids of hTAF II 130 have been reported to interact with the CR3 activation domain of E1A. In that study, the C-terminal fragment of hTAF II 130 was shown to specifically inhibit E1A-mediated transcriptional activation when transiently expressed in mammalian cells (25) .
Although TAFs are present as integral components of the general transcription machinery, individual TAFs might be required by only a subset of activators in a eukaryotic cell. It is possible that short stretches of amino acid residues may be sufficient to provide specific points of contact between a given activator and a TAF. Thus, it is reasonable to envision 8 to 12 TAFs in the TFIID complex providing enough surface for interaction with a large number of activators present in a eukaryotic cell. Posttranslational modifications, differential splicing, and tissue-specific expression of TAFs may further add to the specificity of activator-TAF interactions. Indeed, the recent discovery of a new complex composed of TRF (TBPrelated factor) and novel TAF subunits further increases the repertoire of TAFs required for coactivator function in different cell types (19) . Binding of different activators to different TAFs or to distinct subdomains within the same TAF may allow TFIID to respond to multiple signals from activators bound upstream of the transcriptional initiation site, resulting in the coordinated expression of genes.
